Nab-Paclitaxel as new Therapeutic Option for Pancreatic Cancer

被引：0
|
作者：
Michl, P. [1 ]
机构：
[1] Univ Marburg, Klin Gastroenterol Endokrinol & Stoffwechsel, D-35043 Marburg, Germany
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2013年 / 51卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1329 / 1330
页数：2
相关论文
共 50 条
  • [41] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [42] Gemcitabine and Nab-paclitaxel Induced Complete Response of Advanced Pancreatic Tail Cancer
    Hirakawa, N.
    Itoi, T.
    Sofuni, A.
    Tsuchiya, T.
    Ishii, K.
    Tanaka, R.
    Tonozuka, R.
    Mukai, S.
    Yamamoto, K.
    Asai, Y.
    Matsunami, Y.
    Homma, T.
    Nakatsubo, R.
    PANCREAS, 2021, 50 (07) : 1065 - 1065
  • [43] Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Muranaka, Tetsuhito
    Kuwatani, Masaki
    Komatsu, Yoshito
    Sawada, Kentaro
    Nakatsumi, Hiroshi
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Kubota, Yoshimasa
    Kubo, Kimitoshi
    Kawahata, Shuhei
    Kawakubo, Kazumichi
    Kawakami, Hiroshi
    Sakamoto, Naoya
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 566 - 571
  • [44] The Prognostic Marker of Unresectable Pancreatic Cancer Undergoing Gemcitabine/nab-Paclitaxel Chemotherapy
    Ohno, A.
    Fujimori, N.
    Suehiro, Y.
    Murakami, M.
    Matsumoto, K.
    Teramatsu, K.
    Kojima, F.
    Takamaysu, Y.
    Takaoka, T.
    Oono, M.
    Ogawa, Y.
    PANCREAS, 2019, 48 (10) : 1500 - 1500
  • [45] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
  • [46] Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
    Thapaliya, P.
    Kundranda, M. N.
    Curtis, K. K.
    Callister, M. D.
    Ashman, J. B.
    Collins, J.
    Moss, A.
    Mekeel, K. L.
    Silva, A. C.
    Borad, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Ko, Andrew H.
    Truong, Thach-Giao
    Kantoff, Emily
    Jones, Kimberly A.
    Dito, Elizabeth
    Ong, Anna
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 875 - 881
  • [48] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [50] Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action
    Al-Batran, Salah-Eddin
    Geissler, Michael
    Seufferlein, Thomas
    Oettle, Helmut
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (03) : 128 - 134
12345